Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Clay

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|January 7, 2003
Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytesTimothy M Clay, Michael I Nishimura
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2009
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancerYanal M Murad, Timothy M Clay
Cancer Investigation|August 17, 2011
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune responseErika Hamilton, Timothy M Clay, Kimberly L Blackwell
Expert Opinion on Biological Therapy|April 17, 2002
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenesTimothy M Clay, Michael Morse, H Kim Lyerly
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapyVincent G Brichard, Jamila Louahed, Timothy M Clay
Expert Opinion on Biological Therapy|August 21, 2007
Update on anti-CTLA-4 antibodies in clinical trialsLee F Langer, Timothy M Clay, Michael A Morse
Expert Opinion on Biological Therapy|March 14, 2002
Current status of adoptive immunotherapy of malignanciesMichael A Morse, Timothy M Clay, H Kim Lyerly
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
CEA loaded dendritic cell vaccinesMichael A Morse, Timothy M Clay, H Kim Lyerly
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Recent areas of development for dendritic cell vaccinesMichael A Morse, Steve Chui, Timothy M Clay, et al.
Expert Opinion on Biological Therapy|January 9, 2003
Immunoregulatory T cells in cancer immunotherapyMichael A Morse, Timothy M Clay, Paul Mosca, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Methods in Molecular Biology (Clifton, N.J.)|January 7, 2003
Retroviral transfer of T-cell receptor genes into human peripheral blood lymphocytesTimothy M Clay, Michael I Nishimura
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 10, 2009
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancerYanal M Murad, Timothy M Clay
Cancer Investigation|August 17, 2011
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune responseErika Hamilton, Timothy M Clay, Kimberly L Blackwell
Expert Opinion on Biological Therapy|April 17, 2002
Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenesTimothy M Clay, Michael Morse, H Kim Lyerly
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapyVincent G Brichard, Jamila Louahed, Timothy M Clay
Expert Opinion on Biological Therapy|August 21, 2007
Update on anti-CTLA-4 antibodies in clinical trialsLee F Langer, Timothy M Clay, Michael A Morse
Expert Opinion on Biological Therapy|March 14, 2002
Current status of adoptive immunotherapy of malignanciesMichael A Morse, Timothy M Clay, H Kim Lyerly
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
CEA loaded dendritic cell vaccinesMichael A Morse, Timothy M Clay, H Kim Lyerly
Cancer Chemotherapy and Biological Response Modifiers|September 2, 2004
Recent areas of development for dendritic cell vaccinesMichael A Morse, Steve Chui, Timothy M Clay, et al.
Expert Opinion on Biological Therapy|January 9, 2003
Immunoregulatory T cells in cancer immunotherapyMichael A Morse, Timothy M Clay, Paul Mosca, et al.
Pageof 8